Rekvina Laboratories Financials and Expansion Plans

Rekvina Laboratories has announced its audited standalone financial results for the fiscal year ending March 31, 2026. The company reported a net loss of Rs 25.47 lakh. During the period, total income was Rs 126.54 lakh, against total expenses of Rs 152.01 lakh.

Strategic Growth Initiatives Approved

In addition to its financial performance, the board of Rekvina Laboratories approved significant strategic moves. These include a substantial increase in the company's authorized share capital, raising it from Rs 3.5 crore to Rs 6 crore. This move is a precursor to further corporate actions.

The company also greenlit the acquisition of 100% of Radiant Parenterals Limited for Rs 4.63 crore. The payment for this acquisition will be made through the issuance of equity shares. A separate share subscription agreement was also approved, authorizing the issuance of 4.6 lakh shares for Rs 46 lakh.

Financial Context and Outlook

The reported loss for the fiscal year impacts the company's profitability. However, the approved capital infusion and the acquisition of Radiant Parenterals Limited signal a clear strategy for expansion and future growth. The company's financial reporting follows Indian Accounting Standards (IND AS).

Rekvina Laboratories decided against recommending any dividend for the financial year ended March 31, 2026.

Key Considerations for Investors

Shareholders can expect significant developments as the company proceeds with integrating Radiant Parenterals Limited and managing the new equity issuance. Potential risks include the smooth integration of the acquired business, market acceptance of the new equity, and the company's ability to achieve profitability post-acquisition.

Successful completion of regulatory approvals for the share capital increase and the acquisition will be critical. Investors will be closely watching the company's subsequent financial results to gauge the impact of these strategic decisions.